Home › NCT06590454

REVerse Intestinal Metaplasia in the Stomach (REVISE)

Therapeutic Intervention to Reverse Gastric Precancer

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adults (including men, women, and non-binary individuals) over age 18 with known GIM with at least one high-risk feature (extensive vs limited, incomplete or mixed-type GIM, family history of stomach cancer),
* Ability to provide informed consent,
* Evidence of prior but not active H. pylori infection

Exclusion Criteria:

* Active gastric cancer diagnosis,
* High-risk of bleeding complications due to anticoagulants or underlying medical condition,
* Pregnancy (which is a contraindication to non-emergent endoscopy due to anesthesia risks)

About the study

This study is designed to test the use of Pyrvinium vs placebo as a treatment for gastric intestinal metaplasia with features associated with increased risk of cancer. Response will be determined by assessing the extent and quality of the gastric intestinal metaplasia before and after treatment.

A secondary aim will be to generate gastric organoids from patient-derived samples to test the effects of pyrvinium in vitro in patient-derived samples, and also to identify new drugs that may help reverse gastric intestinal metaplasia.

What is being tested

• Pyrvinium (drug)
• Placebo (drug)

Sponsor: Katherine Garman · Participants: 32 · Started: Dec 15, 2025

Contact the study team

• Nicole Pavlus · Phone: 919-684-0311
• Laura Hayes, MS · Phone: 919-684-8771

Official record on ClinicalTrials.gov — NCT06590454

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.